KAT6 Inhibitors
Disclosed herein are compounds used as inhibitors of KAT6 and pharmaceutical compositions comprising the compounds. Also disclosed are methods for treating a disorder or disease responsive to the inhibition of KAT6 activity in a subject. In an embodiment, the compounds are of formula (I): or a pharmaceutically acceptable salt thereof, or a deuterated analog thereof, or an N-oxide thereof, or a tautomer thereof, wherein values for the variables (e.g., ring B, A 1 , A 2 , A 3 , A 4 , A 5 , X 1 , L, R 62 , R 63 , R 64 , R 7 , and n) are disclosed herein.
1 - 30 . (canceled)
31 . A pharmaceutical composition comprising the compound of claim 33 , or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof, and at least one pharmaceutically acceptable carrier or excipient.
32 . A method of treating breast cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 33 , or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
33 . A compound selected from:
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
34 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
35 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
36 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
37 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
38 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
39 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
40 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
41 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
42 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
43 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
44 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
45 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
46 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
47 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
48 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
49 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.
50 . The compound of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof.